The RTS,S Malaria Vaccine
A WHO recommended vaccine for added protection against malaria to improve child health, save lives and strengthen malaria control in Africa and in other regions with moderate to high malaria transmission

Malaria: An enduring health challenge
Malaria remains a primary cause of childhood illness and death in Africa and holds back prosperity in the region.

- **627K+ DEATHS per year**
- **479K+ CHILD DEATHS PER YEAR**

Malaria has a negative impact on economies

- **USD $12 BILLION** in lost productivity annually worldwide
- **70% LOWER** per capita income levels in endemic countries
- **UP TO 40%** of public health budget of some African countries goes to treating malaria

Malaria progress has stalled. A tailored, optimal mix of tools – including RTS,S – can get malaria control back on track.

- The RTS,S vaccine can be delivered through the existing platform of childhood vaccination that reaches more than 80% of children.

The RTS,S/AS01 malaria vaccine pilots in Africa
Significantly reduces malaria and life-threatening severe malaria. Since 2019, delivered in childhood vaccination in 3 country-led pilots.

- IN 3 YEARS
  - **3 Million+ DOSES**
  - **1 Million+ CHILDREN VACCINATED**

What we know about the RTS,S malaria vaccine in routine use in Africa

**Feasibility**
- Delivery of the vaccine is feasible.
- High, equitable vaccine coverage shown in routine use indicates community demand and the capacity of countries to effectively deliver it.
- No negative impact of vaccination on insecticide-treated bednet (ITN) use, uptake of other childhood vaccines, or care-seeking behaviour

**Equity**
- Increases equity in access to malaria prevention: in routine use, the vaccine reached more than two-thirds of children who are not sleeping under a bednet (ITN)
- Layering the tools results in over 90% of children benefitting from at least one preventive intervention (ITN or the malaria vaccine)

**Impact**
- 1 life saved for every 200 children vaccinated
- 40% reduction in malaria episodes
- Substantial reduction in deadly severe malaria in routine use
- Impact optimized in highly seasonal malaria settings by providing doses prior to peak “rainy” season

To date, more than 2.3 million doses of the vaccine have been administered – the vaccine has a favorable safety profile.

Thank you
Thank you to the Ministries of Health of Ghana, Kenya and Malawi for their leadership and commitment to the RTS,S/AS01 malaria vaccine pilot programme. Thank you to Gavi, the Vaccine Alliance, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Unitaid for their generous support.